PolarityTE Inc.

PolarityTE — Q2 2020 Earnings Presentation

12 slides from PolarityTE's earnings presentation, Aug 6, 2020

  1. Slide 1: Second Quarter 2020 Financial Results

    @ Skinie Calendar Second Quarter 2020 Financial Results August 6, 2020 All Rights

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains forward-looking statements and projections. PolarityTE, Inc, (the "Company") makes no express or implied representation or warrant as to the completeness of this information or, in the case of projections, as to their attainability or the accurac

  3. Slide 3: Opening Remarks

    @ skinte Opening Remarks David Seaburg, Chief Executive Officer

  4. Slide 4: Q2:20 Revenue

    Q2:20 Revenue * Total Revenues: $2.27 million; up 143% QoQ * SkinTE Revenue: $0.94 million; up 121% QoQ * Contract Services Revenue: $1.32 million; up 162% QoQ * Includes $712,000 from COVID-19 test processing © 2020 PolarityTE, Inc. All Rights Reserved,

  5. Slide 5: Recent Notable Achievements

    Recent Notable Achievements * Positive interim results from multi-center randomized controlled trial evaluating SkinTE in the treatment of diabetic foot ulcers (DFUs) * 72% of DFUs treated with SkinTE plus Standard of Care (SOC) closed within 12 weeks vs. 32% of those treated with SOC alone * Apeer-

  6. Slide 6: Q3:20 Guidance

    Q3:20 Guidance * Total Revenue: $2.7 million - $3.2 million * SkinTE Revenue: $1.0 - $1.2 million * Contract Services Revenue: $1.7 million - $2.0 million olarityTE, Inc. All Rights Reserved.

  7. Slide 7: Operational Update

    @ skinte Operational Update Richard Hague, President & COO

  8. Slide 8: Diabetic Foot Ulcer RCT & FDA Update

    Diabetic Foot Ulcer RCT & FDA Update * Diabetic Foot Ulcer RCT * Reported positive interim data July 24, 2020 * 74 enrolled (100 target enrollment) * Expect to reach target enrollment by end of Q4:20 or early Q1:21 * Full data readout expected by early Q2:21 * FDA Meeting Request Submitted on August

  9. Slide 9: Financials

    @ skinte Financials Jake Patterson, Interim CFO. :

  10. Slide 10: Financials

    Financials In USS ‘000 (except per share figures) a aa 2Q.2019 Total Revenues 2,266 Products 944 428 Services 1,322 505 R&D (3,164) (3,373) G&A (5,211) (11,057) S&M (2,024) (3,694) Cash flow from Operations (11,559) (13,854) Cash Investment into PPE (171) (999) Cash, Cash Equivalents and ST 30,504 3

  11. Slide 11: Questions

    @ skinte Questions David Seaburg, CEO Richard Hague, President & COO Jake Patterson, Interim CFO - Nikolai Sopko, MD, PhD, Chief Scientific Officer

  12. Slide 12: About SkinTE

    About SkinTE™ SkinTE is a human cellular and tissue-based product derived from a patient’s own skin (autologous) intended for the repair, reconstruction, replacement, or supplementation of skin tissue. Aseptic surgical procedures and handling during skin harvest, wound preparation, and SkinTE deploy

PolarityTE — Q2 2020 Earnings Presentation on 6ix